<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30197358</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>30</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>30</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1998-4138</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>14</Volume>                    <Issue>5</Issue>                    <PubDate>                        <MedlineDate>2018 Jul-Sep</MedlineDate>                    </PubDate>                </JournalIssue>                <Title>Journal of cancer research and therapeutics</Title>                <ISOAbbreviation>J Cancer Res Ther</ISOAbbreviation>            </Journal>            <ArticleTitle>Efficacy and safety of everolimus in hormone receptor positive breast cancer in a developing country: Real-life single institutional experience.</ArticleTitle>            <Pagination>                <MedlinePgn>1112-1116</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.4103/0973-1482.183552</ELocationID>            <Abstract>                <AbstractText Label="Introduction" NlmCategory="UNASSIGNED">Breast cancer is the second leading cause of cancer-related mortality despite the staggering improvement in cancer therapeutics. So far, published data illustrate endocrine therapy as the cornerstone treatment for patients with hormone receptor-positive metastatic breast cancer. Unfortunately, most patients eventually develop resistance to this treatment.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">The purpose of this study is to evaluate the efficacy of mammalian target of rapamycin inhibition in reversing hormone resistance in the Lebanese breast cancer patients. Efficacy of the intervention according to the independent factors and notable side effects encountered were the primary points of the evaluation.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">In total, fifty patients received the combination of everolimus and exemestane. The mean age of the study population was 61 Â± 11 years. Sensitivity to hormonal therapy before the start of the combination treatment was estimated at 64%. Response rate was 14%, and all patients were partial responders. After regular interval evaluation, the median progression-free survival was 5.2 months since the initiation of therapy. The main toxicities associated with the combination were stomatitis (22%), myalgia (22%), skin toxicity (8%), and hyperglycemia (4%), all Grades 1 and 2.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Everolimus has been shown to be effective in overcoming hormonal resistance in Lebanese breast cancer patients with results inferior to those reported in the BOLERO-2 population. The particular differences in molecular and pathological aspects of breast cancer in our region should stimulate the extensive research for a better understanding of the particular pattern of the disease.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Assi</LastName>                    <ForeName>Tarek</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kattan</LastName>                    <ForeName>Joseph</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>El Rassy</LastName>                    <ForeName>Elie</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tabchi</LastName>                    <ForeName>Samer</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chebib</LastName>                    <ForeName>Ralph</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Moussa</LastName>                    <ForeName>Tania</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hanna</LastName>                    <ForeName>Colette</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>El Karak</LastName>                    <ForeName>Fadi</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Farhat</LastName>                    <ForeName>Fadi</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ghosn</LastName>                    <ForeName>Marwan</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>India</Country>            <MedlineTA>J Cancer Res Ther</MedlineTA>            <NlmUniqueID>101249598</NlmUniqueID>            <ISSNLinking>1998-4138</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>9HW64Q8G6G</RegistryNumber>                <NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003906" MajorTopicYN="N">Developing Countries</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D063806" MajorTopicYN="N">Myalgia</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012871" MajorTopicYN="N">Skin Diseases</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013280" MajorTopicYN="N">Stomatitis</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">everolimus</Keyword>            <Keyword MajorTopicYN="N">hormone resistance</Keyword>            <Keyword MajorTopicYN="N">stomatitis</Keyword>            <Keyword MajorTopicYN="N">toxicity</Keyword>        </KeywordList>        <CoiStatement>There are no conflicts of interest</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30197358</ArticleId>            <ArticleId IdType="pii">JCanResTher_2018_14_5_1112_183552</ArticleId>            <ArticleId IdType="doi">10.4103/0973-1482.183552</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>